Phosphatidylinositol 3-kinase inhibitors for the treatment of lymphoproliferative malignancies

A method of treating a lymphoproliferative malignancy in a human patient in need of such treatment, comprising administering to the patient an effective amount of Compound A

• or a pharmaceutically acceptable salt thereof, wherein the Compound A or pharmaceutically acceptable salt thereof is administered at a continuous once daily dose in capsule form of about 600 mg or at a continuous once daily dose in tablet form of about 200 to about 600 mg, and wherein the lymphoproliferative malignancy is relapsed or refractory.